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a  b  s  t  r  a  c  t
Widespread  legalisation  of  marijuana  raises  safety  concerns  for its  use  in  pregnancy.  This  study  inves-
tigated  the  association  of marijuana  use  prior  to  and  during  pregnancy  with  pregnancy  outcomes  in
a  prospective  cohort  of 5588  nulliparous  women  from  the  international  SCOPE  study.  Women  were
assessed  at  15 ± 1 and  20 ±  1 weeks’  gestation.  Cases  [278  Preeclampsia,  470  gestational  hypertension,
633  small-for-gestational-age,  236  spontaneous  preterm  births  (SPTB),  143  gestational  diabetes]  were
compared  separately  with 4114  non-cases.  Although  the  numbers  are  small,  continued  maternal  mari-
juana use  at  20 weeks’  gestation  was  associated  with  SPTB  independent  of  cigarette  smoking  status  [adj  OR
2.28  (95%  CI:1.45–3.59)]  and  socioeconomic  index  (SEI)  [adj OR 2.17  (95%  CI:1.41–3.34)].  When  adjusted
for  maternal  age,  cigarette  smoking,  alcohol  and  SEI,  continued  maternal  marijuana  use  at  20  weeks’
gestation  had  a greater  effect  size  [adj  OR 5.44 (95%  CI  2.44–12.11)].  Our  data  indicate  that increasing  use
of  marijuana  among  young  women  of reproductive  age  is a  major  public  health  concern.
©  2016  The  Author(s).  Published  by Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
A 2015 conference on medical use of marijuana indicated that
23 US states have legalised medical marijuana with some also
legalising marijuana for recreational use [1]. Although there is
moderate evidence for efficacy of cannabinoids for chronic pain
and spasticity [2], and some evidence for Multiple Sclerosis and
treatment-resistant epilepsy [3–5], there is not good evidence for
its use to treat nausea and vomiting associated with chemotherapy,
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perhaps the best known indication for medical marijuana [6]. Some
pregnant women report using marijuana to alleviate nausea and
vomiting in pregnancy with success [7] but evidence for its efficacy
is mostly anecdotal. However, reports of adverse events for non-
pregnant populations using medical marijuana [6] raise concerns
for pregnant marijuana users.
According to the National Drug Strategy Household Survey [8]
in Australia, 7.6% of females aged ≥14 years used marijuana during
2010 (1% increase compared to 2007), with 34.8% of the female
population having used marijuana at least once in their lifetime. A
similar trend has also been observed in New Zealand and Europe,
with 47.2% of women aged ≥16 years in NZ (from 2007 to 2008)
[9,10], 24.6% in the United Kingdom and 17.5% in Ireland having
used marijuana at least once [11].
Apart from reported negative impacts on fetal growth and
brain development [12–16], marijuana has been associated with
http://dx.doi.org/10.1016/j.reprotox.2016.04.021
0890-6238/© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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adverse pregnancy outcomes, including preterm birth (PTB), small
for gestational age (SGA), placental abruption and antepartum
haemorrhage [17–21]. Specifically, studies have shown that using
marijuana during pregnancy is associated with low birthweight and
increases the risk of PTB and SGA, with an odds ratio of at least 1.5
when adjusted for age, BMI  and smoking [17,20–22].
The association between marijuana use and pregnancy out-
comes is often confounded by other known risk factors including
cigarette smoking, body mass index (BMI), and socioeconomic
index (SEI) [23,24]. Women  who use marijuana also tend to smoke
cigarettes and are more likely to use other drugs and alcohol, for
whom national statistics [25] have shown that amongst Australian
women aged ≥14years who used marijuana in 2010, 82.7% also
consumed alcohol, and 68.5% were cigarette smokers, with similar
patterns of prevalence in New Zealand [10].
There have been inconsistent results reported from American
prospective cohort studies, in which associations of marijuana use
with adverse pregnancy outcomes were either found [21,26,27] or
not found [28–30]. Hence, this study aimed to examine the associ-
ation of maternal marijuana use (from pre-pregnancy and up to 20
weeks’ gestation) in a multi-centre cohort with major pregnancy
complications, amongst both cigarette smokers and non-smokers,
controlling for well-known risk factors including age, SEI and BMI,
as well as its effects on length of gestation.
2. Methods
Data from this analysis were obtained from the SCreening fOr
Pregnancy Endpoints (SCOPE) study, which aimed to build a clin-
ical database and pregnancy biobank to screen candidate markers
of pregnancy complications. The SCOPE study recruited nulliparous
women with singleton pregnancies between November 2004 and
February 2011 from one centre in each of Australia, New Zealand,
and Ireland, and three centres in the United Kingdom. Ethical
approval was obtained from local ethics committees [New Zealand
AKX/02/00/364, Australia REC 1712/5/2008, London, Leeds and
Manchester 06/MRE01/98 and Cork ECM5 (10) 05/02/08] and all
women provided written informed consent.
Women  were invited to participate prior to 15 weeks’ gestation
when attending hospital antenatal clinics, obstetricians, general
practitioners or community midwives, and were interviewed and
examined by a research midwife at 15 ± 1 and 20 ± 1 weeks of ges-
tation.
The exclusion criteria included women who were considered
to be at high risk of PE, SGA or PTB due to underlying medical
conditions (e.g. chronic hypertension requiring antihypertensive
medication or diabetes), previous cervical knife cone biopsy, three
terminations or three miscarriages or if their pregnancy was  com-
plicated by a known major fetal anomaly or abnormal karyotype, or
if they received interventions that may  modify pregnancy outcome
(e.g. aspirin, cervical suture).
Details of maternal age, BMI  and socioeconomic index1 (SEI)
[31], medical and family history, along with dietary and lifestyle
questionnaires with self-reported marijuana and cigarette smok-
ing were recorded at 15 weeks’ and 20 weeks’ gestation and
entered into an internet-accessed, password-protected centralised
database with a complete audit trail (MedSciNetAB, Stockholm,
Sweden) [32].
The number of episodes of marijuana use over 3 months was
also recorded at 15 weeks and 20 weeks of gestation. Other drug
use was also recorded, including cocaine, amphetamines, substance
1 a scale between 10 and 90 generated using an algorithm involving age, income
and education. A higher score indicates higher socioeconomic status. It is a validated
measure of individual socioeconomic status.
P, Ecstasy, opiates, and hallucinogens, with less than 0.6% of women
who have taken these drugs 3 months prior to or during preg-
nancy in SCOPE, but there were insufficient data to be included
for analysis.
Self- reported marijuana and cigarette smoking status were clas-
sified into five categories (i.e. never, quit prior to pregnancy, quit
prior to 15 weeks’ gestation, still using at 15 weeks’ gestation, and
still using at 20 weeks’ gestation) in univariable and multivariable
analysis, with ‘non-smoking’ or ‘never used marijuana’ as the ref-
erence categories. The number of reported episodes of marijuana
use was included as a continuous variable for frequency effect esti-
mation. Use was self-reported where women  provided the number
of joints or cones used.
Spontaneous preterm birth (SPTB) was defined as birth at
less than 37 weeks of gestation that was not a result of medi-
cal or obstetric intervention. Small for gestational age (SGA) was
defined as a birthweight of less than the 10th customised centile,
adjusted for maternal height, weight, parity, ethnicity, gestational
age at delivery and infant sex. Preeclampsia (PE) was defined
as gestational hypertension (GHT) (blood pressure of 140/90 or
greater on at least 2 occasions 4 h apart after 20 weeks’ gesta-
tion) accompanied by proteinuria (300 mg/day or greater, or a spot
protein creatinine ratio of 30 mg/mmol  creatinine or greater). Ges-
tational diabetes mellitus (GDM) was defined as a fasting glucose
of 5.5 mmol/L or higher in a Glucose Tolerance Test, a 2 h level
of 8 mmol  or higher, or a random glucose level of 11 nmol/L or
higher. Universal screening was  not employed for GDM in the UK
and Ireland, where only women  identified at risk based on factors
such as family history and BMI  were screened.
2.1. Statistical analysis
A total of 5588 participants were included in the analysis, with
1155 participants recruited from Australia, 2014 from New Zealand,
1765 from Ireland, and 654 from the United Kingdom. Within the
1514 pregnancies with complications, 278 had PE, 633 had SGA,
236 had SPTB, 470 had GHT, and 143 had GDM (Fig. 1). Details on
age, BMI, SEI, as well as marijuana use and cigarette smoking status
were complete for all participants.
Marijuana and cigarette smoking status were compared
between non-cases and each of the outcomes separately using
Fisher’s exact test. Although about 4% of women (n = 232) had more
than one pregnancy complication, each outcome was  analysed sep-
arately compared with non-cases. Continuous factors, including
maternal age, BMI  and SEI were compared using Student’s t-test.
To investigate the effects of marijuana use between smokers
and non-smokers, analysis of marijuana use, stratified by cigarette
smoking status for each outcome was performed. Breslow-Day
test was  used to assess the homogeneity of the odds of mari-
juana use between cigarette smokers and non-smokers, along with
an adjusted common odds estimated from Mantel-Haenszel test
[33,34].
Marijuana and cigarette smoking status were then analysed
with mixed effects logistic regression to determine the association
with pregnancy outcomes, adjusting for maternal age, BMI  and SEI,
and with recruiting centre differences accounted for as a random
effect. Interaction tests were also performed by comparing logistic
regression models that included interaction terms. A linear mixed
model was also fitted for length of gestation, with quadratic terms
for the number of times marijuana was  used over the preceding 3
months at 15 and 20 weeks of gestation, age, and BMI, to inves-
tigate the dose effect of marijuana and cigarette smoking status
on the length of gestation adjusted for other factors in the model.
The estimated power of this analysis, involving logistic regression
with interaction terms, is 0.99 [35]. All statistical analyses were
performed using R version 3.2.0.
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Late  miscar riage and ot her  compli cations,  n=40
Fig. 1. Participants recruited and study population. Spontaneous preterm birth, SPTB; small for gestational age, SGA; preeclampsia, PE; gestational hypertension, GHT;
gestational diabetes mellitus, GDM.
3. Results
Of the 5588 participants, who were predominantly Caucasian
(Table 1), the overall proportion of women reporting the use of
marijuana before or during pregnancy was 5.6%, with the partici-
pating centre in Australia having the highest rate of women using
marijuana (11.6%), followed by New Zealand (4.5%), Ireland (3.8%),
and United Kingdom (3.7%). Compared to marijuana use, the pro-
portion of cigarette smokers was higher, with an overall 26.4% of
women reporting that they smoked cigarettes before or during
pregnancy. Amongst Australian participants, 40.8% reported they
were cigarette smokers at conception as well as 29.7% of Irish, 29.5%
of UK and 14.2% of NZ participants. Country specific demographics
are shown in Table 1.
The overall characteristics comparing each of the pregnancy
outcomes to non-cases are shown in Table 2. There were signifi-
cant differences in the average BMI  and SEI between non-cases and
all outcomes analysed, where BMI  was higher in women who devel-
oped either PE (27.8 ± 0.38 vs 24.8 ± 0.07 in non-cases; P < 0.001),
GHT (27.9 ± 0.27; P < 0.001), GDM (29.1 ± 0.52; P < 0.001), SGA
(25.9 ± 0.22; P < 0.001) or SPTB (25.4 ± 0.35; P = 0.035). Similarly,
SEI was lower on average in women with complicated pregnan-
cies including PE (38 ± 0.93 vs 42.5 ± 0.26 in non-cases; P < 0.001),
GHT (39.7 ± 0.76; P = 0.001), GDM (38.9 ± 1.36; P = 0.011), and
SGA (40.1 ± 0.64; P = 0.001). Women  who developed PE were also
slightly younger on average (27.7 ± 0.34 vs 28.7 ± 0.09 in non-
cases; P = 0.002), while patients who developed GDM were older
(30 ± 0.44; P = 0.008).
Marijuana use and cigarette smoking at 20 weeks of gestation
were both associated with SGA (18.6% smoking vs only 8.9% in
non-cases; P < 0.001, and 1.9% marijuana use vs 0.7% in non-cases;
P < 0.005) and SPTB (16.1% smoking vs 8.9% in non-cases; P = 0.001,
and 4.7% marijuana use vs 0.7% in non-cases; P < 0.001). For both of
these outcomes, there was a higher proportion of women  who con-
tinued to smoke cigarettes or use marijuana at 20 weeks’ gestation.
In women who delivered a SGA infant, 18.6% continued to smoke
cigarettes (compared to 8.9% in non-cases) and 1.9% continued to
use marijuana (compared to 0.7% in non-cases), while in women
who delivered preterm, 16.1% continued to smoke cigarettes and
4.7% continued to use marijuana at 20 weeks’ gestation.
The proportion of women  reporting any alcohol consumption
(Table 2), from 3 months prior to pregnancy to 20 weeks’ gestation,
was similar in women who  had any complications (less than 77.3%)
compared to non-cases (78.6%). Fewer women with SPTB (10.2%;
P = 0.004), PE (11.5%; P = 0.002), and GDM (10.5%; P = 0.006) contin-
ued to use alcohol at 20 weeks’ gestation compared to non-cases
(15.2%).
Furthermore, amongst women  with SPTB, those who continued
to use marijuana at 20 weeks’ gestation had a significantly shorter
gestation on average of 29.6 ± 1.6 weeks, compared to 34.1 ± 0.3
weeks in those with SPTB who  did not use marijuana (P = 0.005)
(Table 3). The proportion of very early SPTB was  also higher, with
36.4% having delivered at less than 28 weeks of gestation and 63.6%
at less than 32 weeks in women who  continued to use marijuana
at 20 weeks’ gestation, compared to 4.7% and 15.8% amongst non-
users, respectively.
3.1. Interaction between maternal marijuana use and cigarette
smoking
It was important to determine whether the association with
marijuana use was due to concomitant cigarette smoking. Breslow-
Day test showed no evidence of heterogeneity in the association of
marijuana use and pregnancy outcomes between smokers and non-
smokers (P = 0.238), which indicates that the association between
marijuana and SPTB was consistent regardless of cigarette smoking
status. Hence, when comparing any marijuana use, three months
prior to or during pregnancy, between cigarette smokers and non-
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Table  1
Country specific demographics.
Variable Category Overall
(n = 5588)
Australia
(n = 1155)
New
Zealand
(n = 2014)
Ireland
(n = 1765)
United
Kingdom
(n = 654)
Mean ± SEM
N (%)
Mean ± SEM
N (%)
Mean ± SEM
N (%)
Mean ± SEM
N (%)
Mean ± SEM
N (%)
Age 28.6 ± 0.1 23.8 ± 0.2 30.4 ± 0.1 29.9 ± 0.1 28.5 ± 0.2
Ethnicity Caucasian 5061 (89.9) 1067 (91.7) 1707 (84.0) 1733 (97.7) 554 (84.2)
Maori  or
Polynesian
116 (2.1) 6 (0.5) 109 (5.4) 0 (0) 1 (0.2)
Asian  170 (3.0) 42 (3.6) 107 (5.3) 5 (0.3) 16 (2.4)
Indian 134 (2.4) 4 (0.3) 77 (3.8) 22 (1.2) 31 (4.7)
Other 147 (2.6) 45 (3.9) 32 (1.6) 14 (0.8) 56 (8.5)
SEI  41.8 ± 0.2 27.8 ± 0.3 47.9 ± 0.3 42.7 ± 0.4 45.4 ± 0.7
BMI  25.3 ± 0.1 27.0 ± 0.2 24.8 ± 0.1 24.9 ± 0.1 25.0 ± 0.2
Alcohol Yes‡ 4387 (78.0) 643 (55.2) 1584 (78.0) 1604 (90.4) 556 (84.5)
Quit
(pre-preg)
877  (15.6) 182 (15.6) 465 (22.9) 154 (8.7) 76 (11.6)
Quit  (<15
wks)
2487 (44.2) 386 (33.2) 886 (43.6) 948 (53.4) 267 (40.6)
Quit  (<20
wks)
178 (3.2) 34 (2.9) 38 (1.9) 90 (5.1) 16 (2.4)
Yes  (at 20
wks)
845 (15.0) 41 (3.5) 195 (9.6) 412 (23.2) 197 (29.9)
Cigarette
smok-
ing
Yes‡ 1473 (26.4) 471 (40.8) 285 (14.2) 524 (29.7) 193 (29.5)
Quit
(pre-preg)
113  (2.0) 17 (1.5) 40 (2.0) 36 (2.0) 20 (3.1)
Quit  (<15
wks)
699 (12.5) 157 (13.7) 154 (7.7) 294 (16.7) 94 (14.4)
Quit  (<20
wks)
94 (1.7) 41 (3.6) 17 (0.8) 24 (1.4) 12 (1.8)
Yes  (at 20
wks)
567 (10.2) 256 (22.0) 74 (3.7) 170 (9.6) 67 (10.2)
Marijuana Yes‡ 315 (5.6) 134 (11.6) 90 (4.5) 67 (3.8) 24 (3.7)
Quit
(pre-preg)
95  (1.7) 12 (1.0) 45 (2.2) 26 (1.5) 12 (1.8)
Quit  (<15
wks)
145 (2.6) 70 (6.1) 32 (1.6) 35 (2.0) 8 (1.2)
Quit  (<20
wks)
22 (0.4) 14 (1.2) 4 (0.2) 3 (0.2) 1 (0.2)
Yes  (at 20
wks)
53 (1.0) 38 (3.3) 9 (0.5) 3 (0.2) 3 (0.5)
Outcomes SPTB  236 (4.2) 69 (6.0) 87 (4.3) 56 (3.2) 24 (3.7)
SGA  633 (11.3) 141 (12.2) 201 (10.0) 190 (10.8) 101 (15.4)
PE  278 (5.0) 93 (8.1) 85 (4.2) 68 (3.9) 32 (4.9)
GHT  470 (8.4) 118 (10.2) 114 (5.7) 213 (12.1) 25 (3.8)
GDM 143 (2.6) 51 (4.4) 38 (1.9) 44 (2.5) 10 (1.5)
‡ Yes = consumed alcohol/smoked cigarette/used marijuana at least once.
smokers, there was a significant independent association between
any marijuana use and SPTB (P = 0.001).
While the association between marijuana use and SPTB was
independent of smoking status, the Mantel-Haenszel test (Table 5)
further indicated that the overall association was  also signifi-
cant (P < 0.001), with an adjusted common odds of 2.28 (95% CI
1.45–3.59). That is, the odds of SPTB for any marijuana use three
months prior to or during pregnancy was more than doubled for
both cigarette smokers and non-smokers.
Regarding the interaction effect of marijuana in women who
ceased cigarette smoking during pregnancy, results from Breslow-
Day test on the homogeneity of the odds of any marijuana use (three
months prior to or during pregnancy), between women who con-
tinued cigarette smoking before 20 weeks’ gestation and those who
stopped smoking, showed no evidence of heterogeneity (P = 0.541),
with a Mantel-Haenszel adjusted odds of 1.97 (95% CI 1.26–3.09).
This indicated that the effect of marijuana use was not only inde-
pendent of any cigarette smoking three months prior to or during
pregnancy (as reported above), but was also consistent, with nearly
doubled odds, irrespective of whether cigarette smoking ceased
prior to 20 weeks’ gestation.
Results from Logistic regression with an interaction term
between marijuana use and cigarette smoking status also showed
no significant interaction effects on SPTB (P = 0.719).
3.2. Interaction between maternal marijuana use and low
socio-economic status
Interaction between marijuana use and socio-economic sta-
tus was  also tested, and no significant interaction effect was
seen for all pregnancy complications analysed, when added as an
interaction term in multivariable models. When comparing low
socio-economic status, in the lower quartile (SEI <28), with any
marijuana use, Breslow-Day test also showed no evidence of het-
erogeneity (P = 0.656), indicating that the marijuana association
with SPTB was also independent of socio-economic status (adjusted
odds 2.17; 95% CI 1.41–3.34).
3.3. Estimated risk
In logistic regression models controlling for maternal age, SEI,
cigarette smoking, and alcohol consumption (Table 4), continued
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Table 2
Overall demographics for cases vs non-cases.
Variable Category Non-Cases
(n = 4074)
SPTB
(n = 236)
P SGA
(n = 633)
P PE
(n = 278)
P GHT
(n = 470)
P GDM
(n = 143)
P
Mean  ± SEM
N  (%)
Mean ± SEM
N  (%)
Mean ± SEM
N  (%)
Mean ± SEM
N (%)
Mean ± SEM
N  (%)
Mean ± SEM
N  (%)
Age 28.7 ± 0.1 28.3 ± 0.4 0.217 28.6 ± 0.2 0.519 27.7 ± 0.3 0.002 28.8 ± 0.3 0.712 30 ± 0.4 0.008
SEI  42.5 ± 0.3 40.4 ± 1.1 0.059 40.1 ± 0.6 <0.001 38 ± 0.9 <0.001 39.7 ± 0.8 <0.001 38.9 ± 1.4 0.011
BMI  24.8 ± 0.1 25.4 ± 0.4 0.028 25.9 ± 0.2 <0.001 27.8 ± 0.4 <0.001 27.9 ± 0.3 <0.001 29.1 ± 0.5 <0.001
BMI
(cat-
e-
gory)
<20  310 (7.6) 24 (10.2) 0.054 50 (7.9) 0.138 10 (3.6) 0.362 13 (2.8) 0.116 4 (2.8) 0.509
21–25  2187 (53.7) 108 (45.8) Ref 276 (43.6) Ref 96 (34.5) Ref 146 (31.1) Ref 40 (28.0) Ref
26–30  1093 (26.8) 68 (28.8) 0.147 188 (29.7) 0.002 95 (34.2) <0.001 181 (38.5) <0.001 40 (28.0) 0.002
>30  484 (11.9) 36 (15.3) 0.040 119 (18.8) <0.001 77 (27.7) <0.001 130 (27.7) <0.001 59 (41.3) <0.001
Alcohol Yes  3202 (78.6) 168 (71.2) – 489 (77.3) – 192 (69.1) – 389 (82.8) – 95 (66.4) –
Quit
(pre-preg)
639  (15.7) 38 (16.1) 0.195 80 (12.6) 0.063 48 (17.3) 0.147 84 (17.9) 0.034 26 (18.2) 0.225
Quit  (<15
wks)
1813 (44.5) 102 (43.2) 0.044 278 (43.9) 0.503 104 (37.4) 0.000 222 (47.2) 0.043 49 (34.3) 0.001
Quit  (<20
wks)
130 (3.2) 4 (1.7) 0.075 25 (4.0) 0.519 8 (2.9) 0.216 13 (2.8) 0.814 5 (3.5) 0.454
Yes  (at 20
wks)
620 (15.2) 24 (10.2) 0.004 106 (16.8) 0.802 32 (11.5) 0.002 70 (14.9) 0.255 15 (10.5) 0.006
Smoking Yes  1024 (25.1) 69 (29.2) – 213 (33.7) – 70 (25.2) – 138 (29.4) – 34 (23.8) –
Quit
(pre-preg)
85  (2.1) 3 (1.3) 0.459 7 (1.1) 0.195 4 (1.4) 0.473 16 (3.4) 0.049 4 (2.8) 0.597
Quit  (<15
wks)
513 (12.6) 23 (9.8) 0.380 74 (11.7) 0.731 36 (13.0) 0.878 69 (14.7) 0.133 13 (9.1) 0.248
Quit  (<20
wks)
64 (1.6) 5 (2.1) 0.451 14 (2.2) 0.122 6 (2.2) 0.462 9 (1.9) 0.478 2 (1.4) 0.853
Yes  (at 20
wks)
362 (8.9) 38 (16.1) <0.001 118 (18.6) <0.001 24 (8.6) 0.899 44 (9.4) 0.516 15 (10.5) 0.599
Marijuana Yes  217 (5.3) 27 (11.4) – 45 (7.1) – 10 (3.6) – 21 (4.5) – 8 (5.6) –
Quit
(pre-preg)
71  (1.7) 7 (3.0) 0.137 10 (1.6) 0.816 0 (0.0) 0.961 5 (1.1) 0.280 3 (2.1) 0.752
Quit  (<15
wks)
102 (2.5) 7 (3.0) 0.552 18 (2.8) 0.573 8 (2.9) 0.745 14 (3.0) 0.569 3 (2.1) 0.769
Quit  (<20
wks)
14 (0.3) 2 (0.9) 0.202 5 (0.8) 0.104 1 (0.4) 0.979 1 (0.2) 0.637 1 (0.7) 0.492
Yes  (at 20
wks)
30 (0.7) 11 (4.7) <0.001 12 (1.9) 0.005 1 (0.4) 0.471 1 (0.2) 0.219 1 (0.7) 0.962
The bold text indicates significant P-values less than 0.05.
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Table  3
Gestational age at delivery by marijuana use within SPTB cases.
Marijuana n Gestational age (wks) mean ± SEM P <28 wks (n = 21) <32 wks(n = 43) <37 wks(n = 236)
No  209 34.1 ± 0.3 Reference 16 (4.66%) 33 (15.79%) 209 (100%)
Quit  (pre-preg) 7 33.8 ± 1.6 0.934 1 (14.29%) 1 (14.29%) 7 (100%)
Quit  (<15 wks) 7 33.8 ± 1.2 0.649 0 (0%) 2 (28.57%) 7 (100%)
Quit  (<20 wks) 2 33.4 ± 1.0 0.247 0 (0%) 0 (0%) 2 (100%)
Yes  (at 20 wks) 11 29.6 ± 1.6 0.005 4 (36.36%) 7 (63.64%) 11 (100%)
The bold text indicates significant P-values less than 0.05.
use of marijuana at 20 weeks’ gestation was a significant risk fac-
tor for SPTB (OR 5.44; 95% CI 2.44–12.11), but not for any other
outcomes analysed. Similarly, as expected, continuing to smoke
cigarettes at 20 weeks’ gestation was associated with SGA, with
an adjusted odds of 3.46 (95% CI 1.31–9.12).
Elevated BMI  was a significant risk factor for all outcomes
(P < 0.001). By contrast, age was not a significant factor for most
pregnancy outcomes assessed except for GDM (OR 1.08; 95% CI
1.05–1.13) and SGA (OR 1.02; 95% CI 1.00–1.04). Consistent with
previous studies, higher SEI was a protective factor for PE (OR 0.99;
95% CI 0.98–1.00), with an estimated 1–2% decrease in risk for every
unit increase in SEI.
Alcohol consumption after 15 weeks of gestation was  a pro-
tective factor for SPTB, with an odds of 0.34 (95% CI 0.12–0.97)
in women who consumed it after 15 weeks’ but quit before 20
weeks’ gestation, and an odds of 0.52 (95% CI 0.32–0.86) in women
who continued after 20 weeks’ gestation. In contrast, alcohol con-
sumption before 15 weeks’ gestation was associated with increased
risk of GHT, with an odds of 1.80 (95% CI 1.28–2.54) in women
who consumed it in the 3 months prior to pregnancy but stopped
before pregnancy, and an odds of 1.50 (95% CI 1.11–2.02) when
consumed before 15 weeks of gestation. Results from the logistic
regression with interaction terms also showed no significant inter-
action between alcohol consumption and marijuana use for SPTB
(P = 0.935).
3.4. Effect on length of gestation
The results from linear mixed modelling showed that marijuana
use in first (P = 0.000) or second trimester (P = 0.002) had signifi-
cant effects on length of gestation, when adjusted for age, BMI, SEI,
cigarette smoking status, and alcohol consumption. The predicted
length of gestation (Fig. 2) was lower for women who continued
to use marijuana at 20 weeks of gestation for both cigarette smok-
ers and non-smokers, with an estimated gestation of less than 37
weeks when more than 100 episodes of marijuana use within the
previous three months before 20 weeks’ gestation (i.e. more than
once per day for the preceding 3 months).
It should be noted that there was a small but significant decrease
in the predicted length of gestation for cigarette smokers compared
to non-smokers (P = 0.002 at 15 weeks’ gestation, and P = 0.006 at
20 weeks’ gestation). However, our data show that continued mar-
ijuana use at 20 weeks of gestation has a greater effect on gestation
irrespective of cigarette smoking status.
Linear mixed modelling (Fig. 2) indicates a modest reduction in
gestation in women who ceased marijuana use at 15 weeks’ ges-
tation. However, in women who continued to use marijuana at 20
weeks’ gestation, there was a much greater decline in gestational
age at delivery (Fig. 2; Table 2).
4. Discussion
Marijuana use is increasing in women of reproductive age and
its continued use in pregnancy has been of concern for some time
[12]. In addition, we have anecdotal evidence to suggest that some
pregnant women are using marijuana to reduce nausea in early
Fig. 2. Predicted length of gestation and number of episodes of marijuana use in
women who did or did not also smoke cigarettes in the previous 3 months (adjusted
for  age, BMI, SEI, cigarette smoking, and alcohol consumption). Note: actual range
of  marijuana use 0–450 episodes in 3 months.
pregnancy. In this large prospective cohort of nulliparous women
we have demonstrated that continued maternal use of marijuana at
20 weeks’ gestation is a major contributing risk factor for SPTB. Uni-
variable analysis showed a significant association of marijuana use
at 20 weeks’ gestation with SPTB and also SGA, but when adjusted
for other factors, in particular cigarette smoking, marijuana use was
only a significant independent risk factor for SPTB. Furthermore, if
marijuana use was continued at 20 weeks’ gestation, women were
over five times more likely to deliver preterm than nonusers. Of the
women who continued to use marijuana at 20 weeks’ gestation and
delivered preterm, nearly 64% delivered at less than 32 weeks’ ges-
tation. Our data do not have sufficient power to determine whether
there is a gestational age prior to 20 weeks by which it is advisable
to cease marijuana use. Hence, at this stage we  recommend that it
is prudent to abstain from marijuana use during pregnancy.
Based on the current findings and some earlier reports
[17,22,24,36,37], it is likely that maternal marijuana use is an
independent risk factor for SPTB. It has been shown that the
active compound of marijuana (ı9-tetrahydrocannabinol) and its
metabolites are able to cross the placental barrier and thereby have
the potential to directly affect perinatal outcomes [38,39]. Whereas
the results from this study are in agreement with other studies,
it needs to be noted that a few American and a UK prospective
cohort studies did not find an association between marijuana use
and SPTB [28–30,40]. However, these studies have a higher per-
centage (>40%) of black race, whereas there are 89.9% Caucasians
in this study. Although the studies have also adjusted for ethnic-
ity, age, BMI, and other lifestyle factors, interaction tests were not
performed in the analysis to examine the interaction effects of mar-
ijuana use and cigarette smoking on pregnancy outcomes.
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Table 4
Logistic regression model specifications for SPTB, SGA, PE, GHT, and GDM.
Variable Category SPTB P SGA P PE P GHT  GDM
Adj  Odds‡
(95% CI)
Adj Odds‡
(95% CI)
Adj Odds‡
(95% CI)
Adj Odds‡
(95% CI)
P Adj Odds‡
(95% CI)
P
Age 1.02
(0.99–1.04)
0.307 1.02
(1.00–1.04)
0.013 0.98
(0.96–1.01)
0.168 1.01
(0.99–1.03)
0.320 1.08
(1.05–1.13)
<0.001
SEI  1.00
(0.99–1.01)
0.555 0.99
(0.99–1.00)
0.052 0.99
(0.98–1.00)
0.028 0.99
(0.99–1.00)
0.158 0.99
(0.97–1.00)
0.073
BMI  1.03
(1.00–1.06)
0.049 1.04
(1.03–1.06)
<0.001 1.10
(1.08–1.13)
<0.001 1.12
(1.10–1.14)
<0.001 1.13
(1.10–1.16)
<0.001
Alcohol No  Reference Reference Reference Reference Reference
Quit
(pre-preg)
0.82
(0.54–1.24)
0.342  0.82
(0.61–1.11)
0.194 0.93
(0.64–1.36)
0.713 1.80
(1.28–2.54)
<0.001 0.90
(0.54–1.52)
0.697
Quit  (<15
wks)
0.76
(0.55–1.06)
0.109 0.98
(0.78–1.23)
0.830 0.72
(0.53–0.99)
0.042 1.50
(1.11–2.02)
0.008 0.60
(0.38–0.94)
0.026
Quit  (<20
wks)
0.34
(0.12–0.97)
0.044 1.10
(0.68–1.77)
0.710 0.84
(0.39–1.81)
0.652 1.17
(0.62–2.23)
0.629 0.83
(0.31–2.20)
0.703
Yes  (at 20
wks)
0.52
(0.32–0.86)
0.011 1.05
(0.78–1.41)
0.762 0.77
(0.49–1.21)
0.254 1.45
(0.99–2.14)
0.058 0.53
(0.28–1.01)
0.055
Smoking No  Reference Reference Reference Reference Reference
Quit
(pre-preg)
0.74
(0.15–3.58)
0.713  0.93
(0.27–3.12)
0.901 0.32
(0.06–1.86)
0.206 7.17
(1.44–35.71)
0.016 4.60
(0.43–48.92)
0.206
Quit  (<15
wks)
1.01
(0.31–3.31)
0.982 1.56
(0.58–4.15)
0.378 0.42
(0.10–1.79)
0.242 4.35
(0.94–20.14)
0.060 2.67
(0.29–24.78)
0.387
Quit  (<20
wks)
1.56
(0.36–6.69)
0.548 2.33
(0.76–7.10)
0.138 0.49
(0.10–2.49)
0.389 5.42
(1.02–28.89)
0.048 3.53
(0.26–47.74)
0.343
Yes  (at 20
wks)
1.85
(0.58–5.92)
0.302 3.46
(1.31–9.12)
0.012 0.32
(0.07–1.35)
0.120 3.73
(0.80–17.36)
0.094 3.62
(0.40–33.11)
0.254
Marijuana No  Reference Reference Reference Reference Reference
Quit
(pre-preg)
2.23
(0.84–5.86)
0.106  1.08
(0.50–2.33)
0.839 – 0.857 0.91
(0.34–2.45)
0.849 2.53
(0.67–9.60)
0.172
Quit  (<15
wks)
1.32
(0.55–3.17)
0.534 0.95
(0.54–1.65)
0.843 0.74
(0.27–2.03)
0.559 1.50
(0.79–2.85)
0.218 1.47
(0.41–5.28)
0.555
Quit  (<20
wks)
2.76
(0.59–13.01)
0.199 1.64
(0.56–4.83)
0.369 0.90
(0.11–7.37)
0.918 0.63
(0.07–5.30)
0.667 2.13
(0.21–21.30)
0.521
Yes  (at 20
wks)
5.44
(2.44–12.11)
<0.001 1.84
(0.90–3.76)
0.095 0.44
(0.06–3.35)
0.425 0.43
(0.06–3.31)
0.421 1.48
(0.18–11.89)
0.714
Smoking  X Marijuana Interaction
term
1.24
(0.38–4.03)
0.719 1.59
(0.60–4.23)
0.349 0.42
(0.10–1.80)
0.243 4.50
(0.97–20.86)
0.055 3.90
(0.43–35.81)
0.229
The bold text indicates significant P-values less than 0.05.
‡ adjusted for recruitment sites.
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Table  5
Risk of pregnancy complications for any marijuana use (3 months prior to or during pregnancy) adjusted for cigarette smoking status.
Outcomes MarijuanaOdds (95% CI) P-value‡ Odds (95% CI) adjusted for any Smoking* P-value Odds (95% CI)adjusted for Smoking at 20 wks** P-value
SPTB 2.31 (1.45–3.55) <0.001 2.28 (1.49–3.60) <0.001 1.97 (1.26–3.09) 0.004
SGA  1.37 (0.96–1.92) 0.064 1.13 (0.80–1.60) 0.555 1.04 (0.73–1.47) 0.917
PE  0.67 (0.31–1.27) 0.216 0.66 (0.34–1.27) 0.259 0.66 (0.34–1.28) 0.272
GHT  0.74 (0.46–1.19) 0.443 0.25 (0.13–3.54) 0.671 0.81 (0.51–1.30) 0.454
GDM  1.06 (0.44–2.19) 0.877 1.11 (0.52–2.38) 0.949 1.01 (0.48–2.10) 0.986
The bold text indicates significant P-values less than 0.05.
‡ Overall p-value comparing marijuana and corresponding outcome.
* Mantel-Haenszel adjusted odds adjusted for any cigarette smoking (3 months prior to or during pregnancy).
** Mantel-Haenszel adjusted odds adjusted for ceased cigarette smoking at 20 weeks’ gestation.
While African American ethnicity has been associated with an
increased risk of SPTB [41,42], it has also been commonly associ-
ated with lower socio-economic status. The relationship of low SEI
with pregnancy complications was apparent in this study, where
SEI was significantly negatively associated with PE, GHT, GDM, SGA,
and SPTB. When adjusted for age, BMI, cigarette smoking, and mar-
ijuana use, higher SEI was a protective factor, with a 1–2% decrease
in the risk of PE per unit increase in SEI. Similar trends were also
seen in previously published SCOPE data [43,44]. However, the
results from the current study showed no significant interaction
effects between marijuana use and SEI, suggesting that the asso-
ciation between marijuana use and SPTB was also independent of
socio-economic status.
Despite a borderline significance for alcohol consumption at 15
weeks’ gestation for PE risk, our results are consistent with a study
by Klonoff-Cohen et al. [45,46], which showed that maternal alco-
hol consumption does not appear to have a significant association
with preeclampsia. Alcohol consumption during first trimester was
not associated with SPTB, consistent with a previous SCOPE publi-
cation [46]. However, continued alcohol consumption at 20 weeks’
gestation is a protective factor for SPTB, and a recent study by
Lundsberg et al. [47] also showed that alcohol consumption dur-
ing third trimester was associated with a decreased risk of PTB
but not when consumed during early pregnancy. The mechanism
of this effect is still unknown. However, as maternal alcohol con-
sumption may  damage the fetus we cannot recommend it during
pregnancy and indeed the National Health and Medical Research
Council Guidelines recommend against its use in pregnancy [48].
Maternal cigarette smoking is typically considered to be a risk
factor for SPTB and SGA [49–54]. Indeed, maternal cigarette smok-
ing at 20 weeks’ gestation was significantly associated with risk
of SPTB and SGA in univariable tests, but no longer significant for
SPTB when adjusted for other factors, including BMI, SEI, age, and
marijuana. Similar results have been found previously in a study
by Dekker et al. [55], which incorporated multiple novel risk fac-
tors for SPTB. In the current study an association was  seen between
smoking and SPTB (in univariable analysis), but cigarette smoking
was not found to be an independent risk factor for SPTB after adjust-
ment for marijuana use. Nevertheless, continued cigarette smoking
is a significant risk factor for many pregnancy complications includ-
ing stillbirth, placental abruption and SGA and women should be
encouraged to quit before or in early pregnancy [56].
The association between smoking and marijuana is often con-
sidered as an interaction effect for pregnancy complications, as
the majority of women who use marijuana also smoke cigarettes
[10,25,57]. In fact, amongst women who used marijuana in the
SCOPE cohort, 74% also smoked cigarettes. With a high concurrence
rate, the independent effect of marijuana on pregnancy outcomes
has generally been unrecognised and just considered to be sub-
sidiary, partly due to the low availability of data on marijuana use
compared to cigarette smoking for statistical analysis [36,57]. How-
ever, our data from the SCOPE cohort, with 316 participants (5.62%)
who were marijuana users, demonstrate that the association of
marijuana use with SPTB is consistent across cigarette smokers and
non-smokers.
The consistent effect of marijuana use is also apparent when
analysing the effect of the estimated number of episodes of mar-
ijuana use during pregnancy on the length of gestation. While
there was a slight decrease in the predicted length of gestation
amongst smokers, the trend for smokers and non-smokers was
similar. In contrast, the predicted length of gestation for women
who continued to use marijuana at 20 weeks’ gestation was signifi-
cantly decreased compared to those who ceased earlier in gestation,
regardless of smoking status. This is consistent with similar studies
which showed that marijuana use is associated with a decreased
length of gestation [26,27].
Furthermore, apart from a cigarette smoking-marijuana inter-
action, it is also well recognised that cigarette smoking and illicit
drug use are associated with low socio-economic status [57–60],
along with a complex inter-relationship with obesity, where smok-
ing cessation may  also lead to obesity [57,61–63]. As described in
many studies, the prevalence of cigarette smoking and obesity is
higher amongst those who are socio-economically disadvantaged,
and the incidence of SPTB is higher amongst women with lower
income and lower educational status [41,64], which may  indicate
associations with other lifestyle risk factors.
Furthermore, if there was no maternal marijuana exposure, with
an estimated population attributable risk (PAR) of 0.003 for mari-
juana use, the incidence of SPTB would be expected to decrease by
3 cases per 1000 pregnant women. With an overall rate of SPTB of
4.2% in this study, this represents an estimated 6.2% reduction in
the incidence of SPTB in the population, i.e. about 3 out of 50 SPTB
cases would be attributed to marijuana use. If we consider the Aus-
tralian centre only, where any marijuana usage occurred in 11.6% of
women compared to 3.6–4.5% in the other centres, the estimated
PAR was  0.009 for marijuana use with an expected reduction of
SPTB of 9 cases per 1000 pregnant women, and a 11.68% reduction
in the incidence of SPTB in this centre if women  did not use mar-
ijuana. That is, in the Australian study centre, almost 12% of SPTB
could be attributable to maternal marijuana use.
4.1. Strengths and limitations
A major strength of this study was  its large international mul-
ticentre prospective cohort with excellent follow-up and complete
data available for this analysis. Women  were recruited from a
clearly defined population of nulliparous women, with meticulous
data monitoring protocols to reduce data entry or transcription
errors and ensure the quality of data. While there are other stud-
ies that have examined the effect of marijuana use on adverse
pregnancy outcomes, interaction tests were not performed. Hence,
with complete quality data available from this study, interactions
between marijuana use and cigarette smoking status may  be exam-
ined while also adjusting for potential confounders.
It needs to be noted that the number of SPTB cases amongst
women who  reported marijuana use at 20 weeks’ gestation is small
(n = 11) even in this large cohort. The use of self-reported marijuana
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use and cigarette smoking status may  be a potential limitation,
as it may  be subject to participant recall bias. Furthermore, this
study was undertaken in a nulliparous cohort so it may  be the
case that our findings apply only to nulliparous women. Although
medication for maternal asthma, thyroid disease, and PCOS were
recorded, we found no evidence of association with pregnancy out-
comes analysed in this study, therefore these were not included in
the analysis. Further research is required to confirm these findings,
and future studies should include appropriate corrections for the
various important confounders (e.g. smoking, BMI, ethnicity).
5. Conclusion
In this large prospective cohort, maternal marijuana use had
a major contribution to SPTB and this association was  consistent
for both cigarette smokers and non-smokers, with doubled odds in
women who used marijuana three months prior to or during preg-
nancy. For women who use marijuana during pregnancy, it should
be emphasised that stopping early in pregnancy should be encour-
aged since continued use of marijuana at 20 weeks of gestation
was associated with a five-fold increased risk of SPTB in this study
following adjustment for other confounders, including maternal
age, BMI, SEI, and cigarette smoking. In this cohort of nulliparous
women we estimate there would be an estimated 6.2% reduction
in the incidence of SPTB if women were not exposed to marijuana
during pregnancy.
Preterm birth is increasing in developed nations, with attendant
increases in adverse infant outcomes, as well as psychological and
social impacts, and is of great concern to public health. The increas-
ing exposure to marijuana in women of reproductive age and its
contribution to the risk for preterm birth make it a modifiable tar-
get for intervention. In nations where authorities are considering
decriminalisation of marijuana or have already done so, the risks
to pregnant women and their babies need much greater consider-
ation.
Funding
CTR is supported by a National Health and Medical Research
Council (NHMRC) Senior Research Fellowship (GNT1020749). LCK
is supported by a Science Foundation Ireland Program Grant for
INFANT (12/RC/2272). The Australian SCOPE study was  supported
by the Premier’s Science and Research Fund, South Australian
Government, and a NHMRC project grant (GNT519225). The New
Zealand SCOPE study was funded by the New Enterprise Research
Fund, Foundation for Research Science and Technology; Health
Research Council [04/198]; Evelyn Bond Fund, Auckland District
Health Board Charitable Trust. The Irish SCOPE study was funded by
the Health Research Board of Ireland [CSA/2007/2]. The UK SCOPE
study was funded by National Health Service NEAT Grant [Neat
Grant FSD025], Biotechnology and Biological Sciences Research
council [GT084] and University of Manchester Proof of Concept
Funding (University of Manchester); Guy’s and St. Thomas’ Char-
ity (King’s College London) and Tommy’s charity (King’s College
London and University of Manchester); and Cerebra UK (University
of Leeds). The funders had no role in study design, data collection,
and analysis, decision to publish or preparation of the manuscript.
Ethics approval
This study was approved by local ethics committees (New
Zealand AKX/02/00/364, Australia REC 1712/5/2008, London and
Manchester 06/MRE01/98, and Cork ECM5 (10) 05/02/08), and all
women provided written informed consent.
Transparency document
The http://dx.doi.org/10.1016/j.reprotox.2016.04.021 associ-
ated with this article can be found in the online version.
Acknowledgements
The authors wish to thank all of the SCOPE participants and the
SCOPE research midwives in each centre, Robyn North for her con-
tributions in establishing the SCOPE study, and Eliza Chan for her
role in establishing the database. The SCOPE database is provided
and maintained by MedSciNet AB.
References
[1] State Marijuana Laws Map 2015; http://www.governing.com/gov-data/state-
marijuana-laws-map-medical-recreational.html Accessed 1 March 2016.
[2]  K.P. Hill, Medical marijuana for treatment of chronic pain and other medical
and psychiatric problems: a clinical review, JAMA 313 (24) (2015) 2474–2483.
[3] D. Friedman, O. Devinsky, Cannabinoids in the treatment of epilepsy, N. Engl.
J.  Med. 373 (11) (2015) 1048–1058.
[4] O. Devinsky, E. Marsh, D. Friedman, et al., Cannabidiol in patients with
treatment-resistant epilepsy: an open-label interventional trial, Lancet
Neurol. 15 (3) (2016) 270–278.
[5] T.D. Fife, H. Moawad, C. Moschonas, K. Shepard, N. Hammond, Clinical
perspectives on medical marijuana (cannabis) for neurologic disorders,
Neurol. Clin. Pract. 5 (4) (2015) 344–351.
[6] P.F. Whiting, R.F. Wolff, S. Deshpande, et al., Cannabinoids for medical use: a
systematic review and meta-analysis, JAMA 313 (24) (2015) 2456–2473.
[7] R.E. Westfall, P.A. Janssen, P. Lucas, R. Capler, Survey of medicinal cannabis
use among childbearing women: patterns of its use in pregnancy and
retroactive self-assessment of its efficacy against ‘morning sickness’,
Complement. Ther. Clin. Pract. 12 (1) (2006) 27–33.
[8] Australian Institute of Health and Welfare. National Drug Strategy Household
Survey Detailed Report 2013, AIHW, Canberra, 2014.
[9] Ministry of Health. New Zealand Drug Statistics, New Zealand Health
Information Service, Wellington, 2001.
[10] Ministry of Health. Drug Use in New Zealand: Key Results of the 2007/08 New
Zealand Alcohol and Drug Use Survey, Ministry of Health, Wellington, 2010.
[11] European Monitoring Centre for Drugs and Drug Addiction. European Drug
Report: Trends and Developments, Publications Office of the European Union,
Spain, 2013.
[12] N.L. Day, G.A. Richardson, D. Geva, N. Robles, Alcohol, marijuana, and tobacco:
effects of prenatal exposure on offspring growth and morphology at age six,
Alcohol. Clin. Exp. Res. 18 (4) (1994) 786–794.
[13] F.D. Eyler, M.  Behnke, M.  Conlon, N.S. Woods, K. Wobie, Birth outcome from a
prospective, matched study of prenatal crack/cocaine use: I: interactive and
dose effects on health and growth, Pediatrics 101 (2) (1998) 229–237.
[14] X. Wang, D. Dow-Edwards, V. Anderson, H. Minkoff, Y.L. Hurd, Discrete opioid
gene expression impairment in the human fetal brain associated with
maternal marijuana use, Pharmacogenomics J. 6 (4) (2006) 255–264.
[15] R. Hingson, J.J. Alpert, N. Day, et al., Effects of maternal drinking and marijuana
use  on fetal growth and development, Pediatrics 70 (4) (1982) 539–546.
[16] V.B. Faden, B.I. Graubard, Maternal substance use during pregnancy and
developmental outcome at age three, J. Subst. Abuse 12 (4) (2000) 329–340.
[17] M.  Black, S. Bhattacharya, T. Fairley, D.M. Campbell, A. Shetty, Outcomes of
pregnancy in women using illegal drugs and in women who smoke cigarettes,
Acta  Obstet. Gynecol. Scand. 92 (1) (2013) 47–52.
[18] G.T. Gibson, P.A. Baghurst, D.P. Colley, Maternal alcohol, tobacco and cannabis
consumption and the outcome of pregnancy, Aust. N. Z. J. Obstet. Gynaecol. 23
(1) (1983) 15–19.
[19] S. Linn, S.C. Schoenbaum, R.R. Monson, R. Rosner, P.C. Stubblefield, K.J. Ryan,
The association of marijuana use with outcome of pregnancy, Am.  J. Public
Health 73 (10) (1983) 1161–1164.
[20] R. Kennare, A. Heard, A. Chan, Substance use during pregnancy: risk factors
and obstetric and perinatal outcomes in South Australia, Aust. N. Z. J. Obstet.
Gynaecol. 45 (3) (2005) 220–225.
[21] E.E. Hatch, M.B. Bracken, Effect of marijuana use in pregnancy on fetal growth,
Am.  J. Epidemiol. 124 (6) (1986) 986–993.
[22] M.R. Hayatbakhsh, V.J. Flenady, K.S. Gibbons, et al., Birth outcomes associated
with cannabis use before and during pregnancy, Pediatr. Res. 71 (2) (2012)
215–219.
[23] H.L. Brown, C.R. Graves, Smoking and marijuana use in pregnancy, Clin.
Obstet. Gynecol. 56 (1) (2013) 107–113.
[24] E. Kozer, G. Koren, Effects of prenatal exposure to marijuana, Can. Fam.
Physician 47 (2001) 263–264.
[25] , AIHW, Canberra, 2011.
[26] P.A. Fried, B. Watkinson, A. Willan, Marijuana use during pregnancy and
decreased length of gestation, Am.  J. Obstet. Gynecol. 150 (1) (1984) 23–27.
86 S.Y. Leemaqz et al. / Reproductive Toxicology 62 (2016) 77–86
[27] J.J. Janisse, B.A. Bailey, J. Ager, R.J. Sokol, Alcohol, tobacco, cocaine, and
marijuana use: relative contributions to preterm delivery and fetal growth
restriction, Subst. Abus. 35 (1) (2014) 60–67.
[28] M.M. van Gelder, J. Reefhuis, A.R. Caton, M.M.  Werler, C.M. Druschel, N.
Roeleveld, Characteristics of pregnant illicit drug users and associations
between cannabis use and perinatal outcome in a population-based study,
Drug Alcohol Depend. 109 (1-3) (2010) 243–247.
[29] H.S. Bada, A. Das, C.R. Bauer, et al., Low birth weight and preterm births:
etiologic fraction attributable to prenatal drug exposure, J. Perinatol. 25 (10)
(2005) 631–637.
[30] P.H. Shiono, M.A. Klebanoff, R.P. Nugent, et al., The impact of cocaine and
marijuana use on low birth weight and preterm birth: a multicenter study,
Am.  J. Obstet. Gynecol. 172 (1995) 19–27 (1, Part 1).
[31] P. Davis, K. McLeod, M.  Ransom, P. Ongley, The New Zealand Socio-economic
Index of Occupational Status (NZSEI), Statistics New Zealand Research Report,
Wellington, 1997 (No. 2).
[32] L. McCowan, R. North, R. Taylor, ACTRN12607000551493. 2007; www.anzctr.
org.autrialSearch.aspx.
[33] N. Mantel, W.  Haenszel, Statistical aspects of the analysis of data from
retrospective studies of disease, J. Natl. Cancer Inst. 22 (4) (1959) 719–748.
[34] I.M. Liu, Breslow–Day test, in: Encyclopedia of Biostatistics, John Wiley &
Sons, Ltd, 2005.
[35] E. Demidenko, Sample size and optimal design for logistic regression with
binary interaction, Stat. Med. 27 (1) (2008) 36–46.
[36] U. Kesmodel, P.S. Kesmodel, A. Larsen, N.J. Secher, Use of alcohol and illicit
drugs among pregnant Danish women, 1998, Scand. J. Public Health 31 (1)
(2003) 5–11.
[37] H. El Marroun, H. Tiemeier, E.A. Steegers, et al., Intrauterine cannabis
exposure affects fetal growth trajectories: the Generation R Study, J. Am.
Acad. Child Adolesc. Psychiatry 48 (12) (2009) 1173–1181.
[38] A.C. Huizink, Prenatal cannabis exposure and infant outcomes: overview of
studies, Prog. Neuropsychopharmacol. Biol. Psychiatry 52 (2014) 45–52.
[39] D.M. Fergusson, L.J. Horwood, K. Northstone, A.S. Team, Maternal use of
cannabis and pregnancy outcome, BJOG 109 (1) (2002) 21–27.
[40] T.D. Metz, E.H. Stickrath, Marijuana use in pregnancy and lactation: a review
of  the evidence, Am.  J. Obstet. Gynecol. 213 (6) (2015) 761–778.
[41] D.J. Murphy, Epidemiology and environmental factors in preterm labour, Best
Pract. Res. Clin. Obstet. Gynaecol. 21 (5) (2007) 773–789.
[42] R.L. Goldenberg, J.F. Culhane, J.D. Iams, R. Romero, Epidemiology and causes of
preterm birth, Lancet 371 (9606) (2008) 75–84.
[43] J.E. Myers, L.C. Kenny, L.M. McCowan, et al., Angiogenic factors combined with
clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a
predictive test accuracy study, BJOG 120 (10) (2013) 1215–1223.
[44] R.A. North, L.M.E. McCowan, G.A. Dekker, et al., Clinical risk prediction for
pre-eclampsia in nulliparous women: development of model in international
prospective cohort, BMJ  342 (2011) d1875.
[45] H.S. Klonoff-Cohen, S.L. Edelstein, Alcohol consumption during pregnancy and
preeclampsia, J. Womens Health 5 (3) (1996) 225–230.
[46] F.P. McCarthy, L.M. O’Keeffe, A.S. Khashan, et al., Association between
maternal alcohol consumption in early pregnancy and pregnancy outcomes,
Obstet. Gynecol. 122 (4) (2013) 830–837.
[47] L.S. Lundsberg, J.L. Illuzzi, K. Belanger, E.W. Triche, M.B. Bracken,
Low-to-moderate prenatal alcohol consumption and the risk of selected birth
outcomes: a prospective cohort study, Ann. Epidemiol. 25 (1) (2015) 46–54
(e43).
[48] National Health and Medical Research Council. Australian Guidelines to
Reduce Health Risks from Drinking Alcohol. 2009.
[49] A. Braillon, S. Bewley, The enigma of spontaneous preterm birth, N. Engl. J.
Med. 362 (21) (2010) 2032 (author reply 2033–2034).
[50] C.V. Ananth, D.A. Savitz, E.R. Luther, Maternal cigarette smoking as a risk
factor for placental abruption, placenta previa, and uterine bleeding in
pregnancy, Am.  J. Epidemiol. 144 (9) (1996) 881–889.
[51] H.J. Tsai, X. Liu, K. Mestan, et al., Maternal cigarette smoking, metabolic gene
polymorphisms, and preterm delivery: new insights on G×E  interactions and
pathogenic pathways, Hum. Genet. 123 (4) (2008) 359–369.
[52] J. Zhang, M.A. Klebanoff, R.J. Levine, M.  Puri, P. Moyer, The puzzling
association between smoking and hypertension during pregnancy, Am.  J.
Obstet. Gynecol. 181 (6) (1999) 1407–1413.
[53] A. Conde-Agudelo, F. Althabe, J.M. Belizan, A.C. Kafury-Goeta, Cigarette
smoking during pregnancy and risk of preeclampsia: a systematic review, Am.
J.  Obstet. Gynecol. 181 (4) (1999) 1026–1035.
[54] L.M. McCowan, J.M. Thompson, R.S. Taylor, et al., Clinical prediction in early
pregnancy of infants small for gestational age by customised birthweight
centiles: findings from a healthy nulliparous cohort, PLoS One 8 (8) (2013)
e70917.
[55] G.A. Dekker, S.Y. Lee, R.A. North, L.M. McCowan, N.A. Simpson, C.T. Roberts,
Risk factors for preterm birth in an international prospective cohort of
nulliparous women, PLoS One 7 (7) (2012) e39154.
[56] L.M. McCowan, G.A. Dekker, E. Chan, et al., Spontaneous preterm birth and
small for gestational age infants in women who stop smoking early in
pregnancy: prospective cohort study, BMJ  338 (2009) b1081.
[57] M.E. Passey, R.W. Sanson-Fisher, C.A. D’Este, J.M. Stirling, Tobacco, alcohol and
cannabis use during pregnancy: clustering of risks, Drug Alcohol Depend. 134
(2014) 44–50.
[58] P. Tehranifar, Y. Liao, J.S. Ferris, M.B. Terry, Life course socioeconomic
conditions, passive tobacco exposures and cigarette smoking in a multiethnic
birth cohort of U.S. women, Cancer Causes Control: CCC 20 (6) (2009)
867–876.
[59] H. Graham, S.S. Hawkins, C. Law, Lifecourse influences on women’s smoking
before, during and after pregnancy, Soc. Sci. Med. 70 (4) (2010) 582–587.
[60] D.E. Kendzor, M.S. Businelle, L.M. Cofta-Woerpel, et al., Mechanisms linking
socioeconomic disadvantage and BMI  in smokers, Am.  J. Health Behav. 37 (5)
(2013) 587–598.
[61] A. Koster, M.F. Leitzmann, A. Schatzkin, et al., The combined relations of
adiposity and smoking on mortality, Am.  J. Clin. Nutr. 88 (5) (2008)
1206–1212.
[62] M.K. Salonen, E. Kajantie, C. Osmond, et al., Role of socioeconomic indicators
on  development of obesity from a life course perspective, J. Environ. Public
Health 2009 (2009) 625168.
[63] A. Chiolero, D. Faeh, F. Paccaud, J. Cornuz, Consequences of smoking for body
weight, body fat distribution, and insulin resistance, Am.  J. Clin. Nutr. 87 (4)
(2008) 801–809.
[64] P.A. Braveman, K. Heck, S. Egerter, et al., The role of socioeconomic factors in
Black-White disparities in preterm birth, Am.  J. Public Health 105 (4) (2015)
694–702.
